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Abstract: Bone is a complex connective tissue characterized by a calcified extracellular 
matrix. This mineralized matrix is constantly being formed and resorbed throughout life, 
allowing the bone to adapt to daily mechanical loads and maintain skeletal properties and 
composition. The imbalance between bone formation and bone resorption leads to changes 
in bone mass. This is the case of osteoporosis and osteoarthritis, two common skeletal 
disorders. While osteoporosis is characterized by a decreased bone mass and, consequently, 
higher susceptibly to fractures, bone mass tends to be higher in patients with osteoarthritis, 
especially in the subchondral bone region. It is known that these diseases are influenced by 
heritable factors. However, the DNA polymorphisms identified so far in GWAS explain 
less than 10% of the genetic risk, suggesting that other factors, and specifically epigenetic 
mechanisms, are involved in the pathogenesis of these disorders. This review summarizes 
current knowledge about the influence of epigenetic marks on bone homeostasis, paying 
special attention to the role of DNA methylation in the onset and progression of 
osteoporosis and osteoarthritis. 
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1. Bone Cells and Bone Remodeling in Health and Disease 
Bone is a complex connective tissue composed of a calcified extracellular matrix in which different 
cell types are embedded. The complexity of bone is particularly evident in the cells present in this 
OPEN ACCESS 
Biology 2012, 1 699 
 
 
tissue and the multifaceted interactions between them [1]. Bone cells belong to two different families: 
the osteoblastic and the osteoclastic families (see Figure 1) [2,3]. 
Figure 1. Bone is a complex and dynamic organ, which is constantly being remodeled by 
the balanced and coupled activity of the cells present in this tissue. Osteoblasts derive from 
mesenchymal precursors and eventually evolve into osteocytes and lining cells. Cells of the 
osteoblastic lineage are responsible for bone formation. Osteoclasts, derived from 
hematopoietic cells, are responsible for bone resorption. Interestingly, osteoclast 
differentiation is influenced by soluble factors secreted by osteoblasts and osteocytes, 
especially those related to the RANKL-RANK signaling pathway. On the other hand, 
osteocyte-derived sclerostin negatively modulates bone formation. 
 
There are several cell types within the osteoblastic lineage, including osteoblasts, osteocytes and 
lining cells. All of them derive from mesenchymal precursors that differentiate into osteoblasts, which 
eventually evolve into osteocytes or lining cells [4]. Cells of the osteoblastic lineage modulate  
the proliferation and differentiation of cells belonging to the osteoclastic lineage, mainly by the 
RANKL-OPG-RANK signaling pathway [5 7]. Osteocytes derive from some osteoblasts that become 
embedded and surrounded by bone matrix [8]. These cells are emerging as the responders to 
mechanical stimuli that regulate bone formation and resorption, as well as key regulators of bone 
metabolism. Osteocytes modulate bone turnover through the modulation of the Wnt pathway and other 
pathways that influence the activity of both osteoblasts and osteoclasts [9 11].  
Osteoclasts derive from hematopoietic precursors. These cells are formed by the fusion of cells of 
the monocyte-macrophage lineage and are responsible for bone resorption. As mentioned before, 
osteoclastogenesis is influenced by osteoblasts and osteocytes, which produce several factors critical 
for the differentiation of osteoclast precursors, such as the receptor activator of nuclear factor kappa-B 
ligand (RANKL) and the macrophage colony-stimulating factor (MCS-F) [7]. RANKL interacts with 
RANK (Receptor activator of nuclear factor kappa-B), present in the membrane of osteoclastic 
precursors, promoting the activation of the Nuclear factor Kappa B, which induces cell fusion and 
differentiation to originate multinucleated mature osteoclasts [12,13]. It is important to note that 
osteoblastic cells also express osteoprotegerin (OPG), which acts as a soluble decoy receptor for 
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RANKL, thus impairing the RANKL-RANK interaction [14]. Mature osteoclasts locate on specific 
surfaces of bone, where they break down and resorb bone matrix, replacing old bone with new bone [12]. 
Bone is under constant turnover throughout life in order to maintain its properties. It is believed that 
this process, known as bone remodeling, occurs, in part, randomly. However, sometimes, osteocytes 
can mark the site where a remodeling cycle must be started in order to repair microcracks, which 
coupled activity of osteoclasts and osteoblasts. The process starts when osteoclast precursors are 
recruited to the bone surface, where they differentiate and remove a small volume of bone. Then 
osteoclasts undergo apoptosis and osteoblasts arrive to the region to fill up the defect with new  
bone [17]. Bone mass homeostasis depends on the balance between bone formation and bone 
resorption. Any disequilibrium between bone formation and bone resorption leads to changes in bone 
mass. This is the case of osteoporosis and osteoarthritis, two common skeletal diseases that tend to 
show changes of bone mass in opposite directions [18]. 
The maintenance of bone mass requires proper cell differentiation and cell activity. Osteoblast and 
osteoclast differentiation processes are highly organized and driven by deep changes in the gene 
expression patterns that in turn result in cells with different shapes and functions [3,19]. Since bone 
remodeling requires the sequential action of osteoclasts and osteoblasts at a given region, the 
differentiation of both cell types is controlled in a time and site-specific manner, and influenced not 
only by intrinsic factors, but also by some systemic and environmental factors. Emerging lines of 
evidence suggest that epigenetic mechanisms play an important role in establishing cellular identities 
and controlling gene expression. Herein, we summarize the current knowledge about the role of 
epigenetics, and specifically DNA methylation marks, in bone homeostasis and pathogenesis. 
2. DNA Methylation Influences Gene Expression 
Presently, epigenetics is defined as, The study of stable genetic modifications that results in 
changes in gene expression without a corresponding alteration in DNA sequence [20] . Importantly, 
epigenetic marks integrate intrinsic and environmental stimuli and confer both lineage commitment 
and phenotypic plasticity [21]. Thus, epigenetic marks could be considered as a link between  
genotype, environment, phenotype and disease. Epigenetic mechanisms comprise DNA methylation, 
post-translational histone modifications and non-coding RNAs [22,23]. Although the mechanisms of 
epigenetic inheritance during cell division are well established, heritable epigenetic patterns from 
parents to offspring are starting to be revealed [24,25]. 
In eukaryotes DNA methylation consists in the covalent addition of methyl groups to cytosines that 
precede guanines (CpG) [26]. In vertebrate genomes, CpG sites are predominantly methylated [27]. 
However, the globally methylated pattern is disrupted in regions known as CpG islands. These areas 
are present in approximately 70% of gene promoters. On average, CpG islands are 1 kb long, have an 
elevated C + G content and are frequently demethylated [28]. DNA methylation variations do not 
occur exclusively at CpG islands. Recently, it has been also shown that methylation occurs at a short 
distance from the CpG islands (at CpG island shores ), rather than in the islands themselves [29].  
The term CpG island shore refers to regions of lower CpG density that lie in the vicinity (~2 kb) of 
CpG islands. The addition of methyl groups to cytosines is catalyzed by DNA methyltransferases 
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(DNMTs) [30]. DNMT1 was the first methyltransferase identified in mammals [31]. DNMT1 
maintains DNA methylation during cell division by reading and copying the pattern in the 
hemimethylated strand [31]. Other members of the family are DNMT3A, DNMT3B, responsible for  
de novo methylation [32], and DNMT2, which has been recently shown to methylate tRNAs [33]. 
DNA methylation is considered an efficient repressor of transcriptional activity. Until recently, it was 
commonly thought that methyl groups directly prevent the binding of essential transcription factors to 
their targets. Although this is true for a specific set of transcription factors, it is not a general 
phenomenon. In fact, the binding sites for many transcription factors do not have CpGs. Emerging 
evidences support that the presence of methyl groups models the surrounding chromatin, inducing a 
DNA conformation less accessible to the transcription machinery. The mechanisms underlying this 
packing change are not fully understood yet, but many studies have concentrated on nucleosome 
structure, methyl-binding proteins, such as MECP2, MBD2 and MBD3, and interactions with 
chromatin remodeling enzymes [34 36]. Whatever the mechanism, on the basis of its potential to 
silence promoters, DNA methylation is supposed to play an important role in cell commitment and 
cell-specific gene expression. 
How methylation is specifically targeted to a subset of promoters is generating intense debate. 
Apparently, methylation patterns are established early in the embryo [32,37,38]. Several studies 
support the idea that the ultimate methylation profile is determined by the underlying DNA sequence. 
In this sense, it has been shown that local DNA sequence is one of the main determinants for targeting 
DNA methylation to a specific locus. Thus, sequence variation between individuals might contribute to 
differential methylation patterns [38,39]. In fact, recent findings suggest that allele-specific methylation 
(ASM) is a common feature across the genome [40,41]. Notably, most of the ASM is strongly 
associated with SNPs genotypes [42,43]. Subsequent changes in the methylation pattern, generally of a 
tissue-specific nature, occur following implantation (i.e., repression of pluripotent genes) [44,45]. It 
has been proposed that tissue-specific changes occur through mechanisms apparently recruiting 
molecules needed for de novo methylation and demethylation (see Figure 2). Whereas demethylation 
may occur by active or repairing mechanisms [46,47], de novo methylation may be mediated by 
polycomb complexes [48]. 
3. Role of DNA Methylation in Establishing a Bone Cell Phenotype 
An impaired mesenchymal differentiation negatively affects bone mass. Several studies suggest that 
the osteogenic capacity of mesenchymal cells decrease with aging [49]. However, the contribution of 
this event to the decline of bone mass associated with aging is not clear yet. Osteogenic differentiation 
of mesenchymal cells towards osteoprogenitor and osteoblastic cells is regulated by several 
mechanisms, including DNA methylation. Kang et al. demonstrated that promoter methylation 
changes during mesenchymal cell differentiation [50]. Likewise, it has been proposed that active 
demethylation of gene promoters (i.e., osteocalcin, osterix, or Runx2), via GADD45-dependent 
mechanisms, is involved in the ostegenic differentiation of mesenchymal cells [51]. In fact, as reported 
by Locklin et al., osteogenic differentiation may be modulated by demethylating agents [52]. DNA 
methylation marks are not only important in osteoblastogenesis, but also afterwards in the osteoblast to 
osteocyte transition. Our group demonstrated that CpG methylation at regulatory regions controls the 
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expression of the alkaline phosphatase and sclerostin genes. We observed that the hypermethylation of 
ALPL and SOST promoters was inversely correlated with gene expression in osteoblastic cells. 
Furthermore, we showed that the presence of methyl groups at the proximal promoter of SOST 
markedly decreased the transcriptional activity of this sequence, presumably by impairing the binding 
of essential transcription factors to the core promoter. In addition, we demonstrated that the 
methylation of those promoters changes during osteoblast differentiation towards osteocytes and 
controls gene expression in a cell-specific manner [53,54]. DNA methylation at ALPL promoter 
increased progressively during osteoblast differentiation, silencing ALPL expression in osteocytes. 
DNA methylation represses SOST expression in osteoblasts, whereas the physiological demethylation 
of its promoter favored the expression of this gene in osteocytes (see Figure 2). Consistent with this 
observation, SOST promoter remains methylated in other cell types that do not express sclerostin [53]. 
The results of other investigators also support that the expression of a number of genes important for 
osteogenic differentiation and osteoblast/osteocyte activity (including podoplanin, osteopontin, 
Brachury transcription factor, estrogen receptor, aromatase, collagen cross-linking enzyme lysyl 
oxidase or the homeobox protein Dlx-5) is regulated by DNA methylation [55 62]. 
Figure 2. Dynamics of tissue-specific DNA methylation of bone cells. DNA methylation is 
established early in the embryo. Generally, at this stage, pluripotent genes and house-keeping 
genes are unmethylated, whereas tissue-specific genes are largely methylated. Then, the 
differentiation to mesenchymal cells promotes not only demethylation of many of these 
specific cell lineage genes, but also de novo methylation events to silence multipotent-specific 
genes. During mesenchymal commitment to the osteoblastic lineage, some unmethylated 
genes undergo de novo methylation to be silenced in osteocytes, such as alkaline 
phosphatase gene (ALPL). However, other methylated genes are actively demethylated to 
promote its expression in the late osteocyte [sclerostin (SOST)]. Lastly, other genes already 
demethylated in mesenchymal cells remain demethylated in differentiated cells, such as the 
Receptor activator of nuclear factor kappa-B ligand (RANKL). Black and white circles 
represent DNA methylation and hypomethylation, respectively. 
 
On the other hand, DNA methylation contributes to regulate self-renewal and differentiation 
capacity of hematopoietic cells, the early precursors of osteoclasts [63]. The subsequent differentiation 
of osteoclast precursors towards mature osteoclasts is tightly regulated by soluble factors secreted  
by osteoblasts and osteocytes, such as RANKL, OPG and MCS-F [7,64]. As first reported by  
Kitazawa et al., and recently confirmed by our group in human samples, RANKL and OPG expression 
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is regulated by DNA methylation in osteoblastic cells [65,66]. CpG methylation at the regulatory 
regions of RANKL and OPG genes is associated with low transcript levels. In turn, the demethylation 
of their promoters mediated by 5-azadeoxycitidine, a demethylating agent, induces the expression of 
both genes. Based upon these evidences, epigenetic mechanisms appear to be important for osteoclast 
differentiation (reviewed by Yasui et al. [67]). However, it is worth emphasizing that besides DNA 
methylation, other epigenetic marks, such as microRNAs or chromatin modifiers, are also involved in 
determining the differentiation and activity of bone cells, recently reviewed by Delgado-Calle et al., 
Kato S et al. and Earl CS et al. [68 70]. 
4. Methylation Marks and Common Skeletal Diseases 
4.1. Osteoporosis 
Osteoporosis is characterized by reduced bone mass and/or abnormal bone microarchitecture, which 
decrease bone strength and augment the susceptibility to fracture. Common osteoporotic fractures 
include those of the vertebral bodies, hip, pelvis, proximal arm and wrist. Any imbalance in the 
activity of osteoclasts and osteoblasts in a way such that bone formation is smaller than bone 
resorption results in osteoporosis. In some cases, osteoporosis is secondary to an underlying disease, 
but quite often it is just an exaggeration of the universal age-associated decrease in bone mass. In part, 
it is related to the diminished availability of sex steroids taking place in women after menopause and in 
elderly men [71], but other incompletely known factors associated with aging are likely involved [49,72]. 
Whatever those mechanisms might be, osteoporosis is the final result of the complex interplay between 
genetic and acquired factors in which epigenetic marks may also participate. 
As discussed above, experimental evidence shows that the methylation of several genes play a 
major role in the differentiation of bone cells, which is required to sustain a normal bone remodeling. 
Therefore, it might be hypothesized that DNA methylation is involved in the pathogenesis of 
osteoporosis, though there is little evidence directly supporting this hypothesis so far. However, it has 
been recently proposed that reduced Dnmt1 activity decreases bone mineral density and body  
weight [73]. A number of studies suggest that environmental influences may contribute to shaping the 
methylation pattern of the individual and that the pattern may change in association with aging [74 78]. 
Several animal studies have related the environmental factors during early phases of development with 
DNA methylation and skeletal status. In fact, maternal dietary intake has been shown to influence bone 
mass of the offspring, both in experimental animals and in humans [79]. In some cases, DNA 
methylation may be involved. For instance, dietary restriction of pregnant rats induces changes in the 
methylation of genes that are important for bone cell differentiation and activity, such as the 
glucocorticoid receptor and the peroxisomal-activated receptor genes [80 83]. 
4.2. Osteoarthritis 
Whereas osteoporosis is primarily a bone disorder, osteoarthritis is the most common form of joint 
disease. In fact, damage of the articular cartilage is the hallmark of osteoarthritis. However, 
osteoarthritis involves an abnormal remodeling of other tissues in affected joints, such as the synovium 
and the subchondral bone [84,85]. Thus, other typical changes in the joints of patients with 
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osteoarthritis (besides the narrowing of joint space secondary to cartilage thinning), include the 
formation of osteophytes (bone excrescences at the periphery of the joints) and sclerosis of the 
subchondral bone. The extracellular matrix of the articular cartilage contains several types of collagen 
(II, IX and XI) and proteoglycanes, such as aggrecan. Several investigators have shown an altered 
homeostasis in the diseased cartilage, with increased expression of catabolic genes, accompanied by a 
diminished synthesis of components of the cartilaginous matrix. Matrix metalloproteases (MMPs) and 
aggrecanases (ADAMTS-4 and 5) are regarded as major enzymes mediating the destructive process of 
cartilage. The sclerosis of subchondral bone used to be considered a secondary reactive change, but in 
recent years, the concept is emerging that subchondral bone may play more than a passive role in the 
pathogenesis of the disease. In line with this concept, it has been postulated that cytokines released by 
bone cells influence the activity of chondrocytes, and vice-versa [86]. Furthermore, subchondral bone 
influences the overlying cartilage, not only through its biomechanical properties, but also through the 
synthesis of various humoral factors (see recent reviews [86 90]). 
After the seminal work by Roach et al. [91,92], it has been demonstrated that, in some cases, 
changes in chondrocyte gene expression are associated with inverse changes in DNA methylation. For 
instance, Zimmerman et al. reported that the induction of type X collagen expression during 
chondrogenic differentiation of mesenchymal stem cells is associated with the demethylation of 
specific CpGs in its promoter [93]. However, in adult chondrocytes, the promoter was methylated, 
which correlated with the absence of gene expression. Inverse correlations between methylation and 
gene expression have been reported for other genes, including osteogenic protein 1 (OP-1), interleukin 
1 beta, MMP3, MMP9, MMP13, leptin and ADMTS4 [58,94,95]. The exact molecular mechanisms 
have not been completely elucidated, but in some cases they may include methylation-dependent 
differences in the ability to recruit transcription factors, such as CREB, to gene regulatory regions [96]. 
However, gene expression and DNA methylation are not always inversely correlated. Thus, the 
reduced expression of genes, such as type II collagen or aggrecan reported in diseased cartilage, does 
not seem to be associated with increased methylation of these genes [94,97]. On the other hand, the 
functional consequences of gene methylation have also been revealed by in vitro experiments, showing 
that inducing DNA demethylation by 5-azadeoxycitidine modulates the differentiation of articular 
chondrocytes [98].  
Some data suggest that the shape of the bones may also influence osteoarthritis. For instance, 
epidemiological studies showed that the certain morphological characteristics of the femoral epiphysis 
and the pelvis determine the risk of hip osteoarthritis [99 101]. This has given support to the 
hypothesis of a developmental origin of osteoarthritis [102 104]. The importance of developmental 
factors is also emphasized by recent results from genome-wide association studies [105,106]. 
Somewhat unexpectedly, these studies have not revealed significant associations between osteoarthritis 
and genes typically involved in cartilage homeostasis, such as those encoding proteases. Instead, they 
have shown association between some polymorphisms of genes involved in joint development, such as 
GDF5, and osteoarthritis of the large joints, particularly the knee and the hip [107,108]. It is currently 
thought that the epigenome is the consequence of environmental factors, genetic features and 
stochastic variations. In this regard, it is interesting to note that some GDF5 single nucleotide 
polymorphisms (SNPs) showed differential allelic expression. Interestingly, the functional effect of 
on [108]. 
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Our group has recently published a genome-wide methylation study in bone samples obtained from 
patients with severe hip osteoarthritis and compared the results with those obtained in patients with 
osteoporotic hip fractures [109]. Our results revealed several genes showing differential methylation 
between osteoporotic and osteoarthritic patients. Somewhat unexpectedly, genes showing differential 
methylation where not typical bone candidates. However, functional network analysis revealed that 
epige -known 
bone-related genes. Interestingly, and in tune with the developmental hypothesis, we found that genes 
showing differential methylation were overrepresented in pathways related to skeletal development, 
and particularly those of the homeobox family. Globally, DNA methylation correlated negatively with 
gene expression in both groups of patients. However, as observed in other studies, we found a subset 
of genes in which there was no inverse correlation between DNA methylation and the abundance of 
gene transcripts, thus pointing out that factors other than methylation play an important role in the fine 
tuning of gene expression in adult tissues. 
4.3. Tumors and Bone 
Some tumors originate in the skeleton, and many others have a propensity to metastasize in bone. In 
fact, bone metastases are very common in a variety of advanced cancers and contribute importantly to 
cancer morbidity. The mechanisms influencing the metastatic potential of tumor cells and their tropism 
for certain tissues are being actively investigated. They are likely complex and include factors related 
to the tumor itself and others which depend on the tissue hosting the metastases. In some cases, they 
may include certain methylation patterns that result in specific gene expression signatures that 
facilitate the initiation or the growth of the metastases. Prostate cancer cells are among those with a 
stronger tropism for bone. Saha et al. reported that the hypomethylation of the E-cadherin gene, and 
the subsequent reduction of gene expression, was associated with metastatic prostate cancer cells in 
bone [110]. Also, reduced DNA methylation is associated with increased expression of the parathyroid 
hormone-related protein (PTHrP) by breast cancer cells, which in turn may facilitate osteolysis and the 
growth of the metastatic niche [111]. On the other hand, the fact that certain tumors have specific gene 
methylation patterns, different from those of normal tissues, has raised the possibility of using the 
analysis of DNA remnants present in serum as a biomarker to help in diagnosing specific types  
of cancer.  
5. Concluding Remarks 
Common skeletal disorders, such as osteoporosis and osteoarthritis, are the result of a complex 
interplay of genetic and acquired factors. However, despite tremendous efforts, including several 
GWAS, the genetic factors so far identified explain less than 10% of the genetic risk. This suggests 
that mechanisms not related to DNA sequence may be involved in the development of these diseases. 
This could be the case of DNA methylation and its mediators. DNA methylation marks are heritable, at 
least through cell divisions, control gene response to environment, change with aging and underlie cell 
commitment and the spatiotemporal control of gene expression. DNA methylation plays an important 
role in the differentiation of cells of the osteoblastic and osteoclastic lineages. Therefore, it is tempting 
to speculate that the aberrant phenotypes observed in bone diseases might be the consequence of a 
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combination of intrinsic and environmental factors, including gene sequence variations and epigenetic 
signatures (see Figure 3). However, it is important to note that DNA methylation is only one of the 
mechanisms underlying gene expression. Thus, the integration of knowledge from both epigenenomics 
i.e., transcriptomics, proteomics) will be essential for the 
full understanding of the underlying mechanisms that govern the initiation and progression of bone 
diseases. Although still a long way to go, further studies in bone epigenetics may open a new door for 
drug development combining genetic and epigenetic strategies. 
Figure 3. Factors involved in epigenetic variability. Epigenetic marks can change 
throughout life and, thereby, determine the adult phenotypes of the cells present in bone. 
Several factors (i.e., starving) may influence epigenetic marks at different stages of 
intrauterus life. For instance, genetic inheritance might influence the de novo methylation 
that occurs before implantation. Likewise, stochastic variations and environmental cues 
may also influence the epigenetic pattern. During the post-natal life, epigenetic variability 
may depend on environmental (i.e., toxic habits, food...) and intrinsic factors (genetic 
predisposition), as well as on the occurrence of DNA somatic mutations. Epigenetic 
signatures are directly linked to the control of cell differentiation and gene expression, thus 
accumulated epigenetic variability can lead to aberrant phenotypes and, consequently, 
induce skeletal disease. 
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